HyperlipidemiaNCT07907081

Comparative Analysis of Chamomile Tea (Matricaria Chamomilla) and Green Tea (Camellia Sinensis) Against Hyperlipidemia

A study testing Chamomile tea (Matricaria chamomilla) and Green tea (Camellia sinensis) in people with Hyperlipidemia and Normal, run by Iahtisham-Ul-Haq at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Any age, men onlyHealthy volunteers can take part
Conditions the study is for: Hyperlipidemia, Normal
What is being tested?: Chamomile tea (Matricaria chamomilla) and Green tea (Camellia sinensis)
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 25 participants
Where: 1 sitePakistan
Study dates: 12 Nov 2018to 15 Mar 2019
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
Men only
Healthy volunteers accepted
Child, Adult, Older adult

Who may be able to join

Individuals with Hyperlipidemia with with no preexisting disorders like diabetes or history of drug abuse were selected for study II.

Who cannot join

Individuals diagnosed with a chronic disease, mental or physical illness, and smokers were excluded from the trial.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site

Imperial College of Business Studies
Lahore, Punjab Province

Other trials in Pakistan

About this study

Official title: Comparative Analysis of Chamomile Tea and Green Tea Against Hyperlipidemia

Present study was conducted to compare the efficacy of green tea (Camellia sinensis) and chamomile tea (Matricaria chamomilla), administered individually, as a combined intervention, and as a sequential (morning/evening) regimen on glycemic, lipid, hepatic, and renal biomarkers in normal and hyperlipidemic subjects. Two parallel studies were conducted: Study I assessed the effects of intervention on normal subjects while Study II assessed the effect in hyperlipidemic subjects. Both studies consisted of an untreated control group and four tea-based intervention groups. The biochemical parameters including fasting blood glucose (FBG), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), high-density lipoprotein (HDL), triglycerides (TG), total cholesterol (TC), aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), bilirubin, urea, and creatinine were measured at baseline (Day 1) and after 30 days of intervention.

Conditions: Hyperlipidemia, Normal
Being tested: Chamomile tea (Matricaria chamomilla), Green tea (Camellia sinensis)
Medical subject headings: Hyperlipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Chamomile tea (Matricaria chamomilla)Other
Chamomile tea (200 ml) per day for 30 days/ Chamomile tea (100 ml) and Green tea (100 ml) combined per day for 30 days/ Green tea (100 ml) in the morning and Chamomile tea (100 ml) in the evening per day for 30 days
Green tea (Camellia sinensis)Other
Green tea (200 ml) per day for 30 days/ Chamomile tea (100 ml) and Green tea (100 ml) combined per day for 30 days/ Green tea (100 ml) in the morning and Chamomile tea (100 ml) in the evening per day for 30 days

Study groups in NCT07907081
Study group	Role	What they receive
Green tea - Normal subjects	Experimental	Normal subjects who prepared and drank 200 ml of green tea per day for 30 days Receives: Other: Green tea (Camellia sinensis)
Chamomile tea - Normal subjects	Experimental	Normal subjects who prepared and drank 200 ml of chamomile tea per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla)
Chamomile tea and Green tea Combined - Normal subjects	Experimental	Normal subjects who prepared and drank a mixed tea of 100 ml green tea and 100 ml of chamomile tea per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla); Other: Green tea (Camellia sinensis)
Green tea (morning) and Chamomile tea (evening) - Normal subjects	Experimental	Normal subjects who prepared and drank 100 ml of green tea in the morning and 100 ml of chamomile tea in the evening per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla); Other: Green tea (Camellia sinensis)
Control - Normal subjects	No intervention	Normal subjects who did not drink any tea
Green tea - Hyperlipidemic patients	Experimental	Hyperlipidemic patients who prepared and drank 200 ml of green tea per day for 30 days Receives: Other: Green tea (Camellia sinensis)
Chamomile tea - Hyperlipidemic patients	Experimental	Hyperlipidemic patients who prepared and drank 200 ml of chamomile tea per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla)
Chamomile tea and Green tea Combined - Hyperlipidemic patients	Experimental	Hyperlipidemic patients who prepared and drank a mixed tea of 100 ml of green tea and 100 ml of chamomile tea per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla); Other: Green tea (Camellia sinensis)
Green tea (morning) and Chamomile tea (evening) - Hyperlipidemic patients	Experimental	Hyperlipidemic patients who prepared and drank 100 ml of green tea in the morning and 100 ml of chamomile tea in the evening per day for 30 days Receives: Other: Chamomile tea (Matricaria chamomilla); Other: Green tea (Camellia sinensis)
Control - Hyperlipidemic patients	No intervention	Hyperlipidemic patients who did not drink any tea

What is being measured

The primary outcome is the main question the study is designed to answer.

Serum Low-density lipoprotein (LDL) cholesterol concentration (milligrams per deciliter)
LDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum High-density lipoprotein (HDL) cholesterol concentration (milligrams per deciliter)
HDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum Very low-density lipoprotein (VLDL) cholesterol concentration (milligrams per deciliter)
VLDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum total cholesterol concentration (milligrams per deciliter)
Total cholesterol was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics.
Measured: Baseline and 30 days
Serum triglycerides concentration (milligrams per deciliter)
Triglycerides were measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days

Secondary outcomes (7)

Fasting Blood Glucose concentration (milligrams per deciliter)
Fasting Blood Glucose was measured by using enzymatic method in Roche Modular P chemistry analyzer
Measured: Baseline and 30 days
Serum alanine aminotransferase (ALT) concentration (milligrams per deciliter)
ALT was measured by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum aspartate aminotransferase (AST) concentration (milligrams per deciliter)
AST was measured by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum alkaline phosphatase (ALP) concentration (milligrams per deciliter)
ALP was measured by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum bilirubin concentration (milligrams per deciliter)
Bilirubin was measured by using Hitachi 704 analyzer serviced by Roche diagnostics
Measured: Baseline and 30 days
Serum urea concentration (milligrams per deciliter)
Urea was analyzed with refrigerated serum in Beckman Synchron LX20
Measured: Baseline and 30 days
Serum creatinine concentration (milligrams per deciliter)
Creatinine was analyzed with refrigerated serum in Beckman Synchron LX20
Measured: Baseline and 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

12 Nov 201815 Mar 2019

First posted30 Oct 2026
Study start12 Nov 2018
Primary completion15 Mar 2019
Study completion15 Mar 2019

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for HyperlipidemiaStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Two parallel studies were conducted: Study I assessed the effects of intervention on normal subjects while Study II assessed the effect in hyperlipidemic subjects. Both studies consisted of an untreated control group and four tea-based intervention groups.
Masking: None (open label)
Enrolment: 25 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07907081
Sponsor's protocol ID: PHND02163008
Status last verified: Oct 2026
First submitted: 25 Oct 2026
Last updated: 4 Nov 2026
Results posted: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia

All Hyperlipidemia trials

Study at a glance

From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Comparative Analysis of Chamomile Tea and Green Tea Against Hyperlipidemia
ClinicalTrials.gov ID: NCT07907081
Acronym / sponsor ID: PHND02163008
Conditions: Hyperlipidemia, Normal
Study type: Interventional
Recruitment status: Completed
Enrolment: 25 participants (actual)
Lead sponsor: Iahtisham-Ul-HaqUniversity, hospital or other
Study start: 12 Nov 2018 (actual)
Primary completion: 15 Mar 2019 (actual)
Study completion: 15 Mar 2019 (actual)
First posted: 30 Oct 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 10
Model description: Two parallel studies were conducted: Study I assessed the effects of intervention on normal subjects while Study II assessed the effect in hyperlipidemic subjects. Both studies consisted of an untreated control group and four tea-based intervention groups.

Arm	Type	Receives
Green tea - Normal subjects	Experimental	Other: Green tea (Camellia sinensis)Normal subjects who prepared and drank 200 ml of green tea per day for 30 days
Chamomile tea - Normal subjects	Experimental	Other: Chamomile tea (Matricaria chamomilla)Normal subjects who prepared and drank 200 ml of chamomile tea per day for 30 days
Chamomile tea and Green tea Combined - Normal subjects	Experimental	Other: Chamomile tea (Matricaria chamomilla), Other: Green tea (Camellia sinensis)Normal subjects who prepared and drank a mixed tea of 100 ml green tea and 100 ml of chamomile tea per day for 30 days
Green tea (morning) and Chamomile tea (evening) - Normal subjects	Experimental	Other: Chamomile tea (Matricaria chamomilla), Other: Green tea (Camellia sinensis)Normal subjects who prepared and drank 100 ml of green tea in the morning and 100 ml of chamomile tea in the evening per day for 30 days
Control - Normal subjects	No intervention	–Normal subjects who did not drink any tea
Green tea - Hyperlipidemic patients	Experimental	Other: Green tea (Camellia sinensis)Hyperlipidemic patients who prepared and drank 200 ml of green tea per day for 30 days
Chamomile tea - Hyperlipidemic patients	Experimental	Other: Chamomile tea (Matricaria chamomilla)Hyperlipidemic patients who prepared and drank 200 ml of chamomile tea per day for 30 days
Chamomile tea and Green tea Combined - Hyperlipidemic patients	Experimental	Other: Chamomile tea (Matricaria chamomilla), Other: Green tea (Camellia sinensis)Hyperlipidemic patients who prepared and drank a mixed tea of 100 ml of green tea and 100 ml of chamomile tea per day for 30 days
Green tea (morning) and Chamomile tea (evening) - Hyperlipidemic patients	Experimental	Other: Chamomile tea (Matricaria chamomilla), Other: Green tea (Camellia sinensis)Hyperlipidemic patients who prepared and drank 100 ml of green tea in the morning and 100 ml of chamomile tea in the evening per day for 30 days
Control - Hyperlipidemic patients	No intervention	–Hyperlipidemic patients who did not drink any tea

Who may qualify

Sex: Male only
Healthy volunteers: Accepted
Age groups: Child, Adult, Older adult

Key inclusion criteria (1 listed)

Individuals with Hyperlipidemia with with no preexisting disorders like diabetes or history of drug abuse were selected for study II.

Key exclusion criteria (1 listed)

Individuals diagnosed with a chronic disease, mental or physical illness, and smokers were excluded from the trial.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Chamomile tea (Matricaria chamomilla)Chamomile tea (200 ml) per day for 30 days/ Chamomile tea (100 ml) and Green tea (100 ml) combined per day for 30 days/ Green tea (100 ml) in the morning and Chamomile tea (100 ml) in the evening per day for 30 days	Other	Chamomile tea - Hyperlipidemic patients, Chamomile tea - Normal subjects, Chamomile tea and Green tea Combined - Hyperlipidemic patients, Chamomile tea and Green tea Combined - Normal subjects, Green tea (morning) and Chamomile tea (evening) - Hyperlipidemic patients, Green tea (morning) and Chamomile tea (evening) - Normal subjects
Green tea (Camellia sinensis)Green tea (200 ml) per day for 30 days/ Chamomile tea (100 ml) and Green tea (100 ml) combined per day for 30 days/ Green tea (100 ml) in the morning and Chamomile tea (100 ml) in the evening per day for 30 days	Other	Chamomile tea and Green tea Combined - Hyperlipidemic patients, Chamomile tea and Green tea Combined - Normal subjects, Green tea (morning) and Chamomile tea (evening) - Hyperlipidemic patients, Green tea (morning) and Chamomile tea (evening) - Normal subjects, Green tea - Hyperlipidemic patients, Green tea - Normal subjects

Primary outcome

Serum Low-density lipoprotein (LDL) cholesterol concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
LDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Serum High-density lipoprotein (HDL) cholesterol concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
HDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Serum Very low-density lipoprotein (VLDL) cholesterol concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
VLDL was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics
Serum total cholesterol concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Total cholesterol was measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics.
Serum triglycerides concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Triglycerides were measured according to enzymatic reactions in serum or plasma by using Hitachi 704 analyzer serviced by Roche diagnostics

7 secondary outcomes

Fasting Blood Glucose concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum alanine aminotransferase (ALT) concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum aspartate aminotransferase (AST) concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum alkaline phosphatase (ALP) concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum bilirubin concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum urea concentration (milligrams per deciliter)
Time frame: Baseline and 30 days
Serum creatinine concentration (milligrams per deciliter)
Time frame: Baseline and 30 days

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
Individual participant dataSharing planned: No

Related trials for Hyperlipidemia

Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Chamomile tea (Matricaria chamomilla) and Green tea (Camellia sinensis) in people with Hyperlipidemia and Normal, run by Iahtisham-Ul-Haq at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum Low-density lipoprotein (LDL) cholesterol concentration (milligrams per deciliter) (time frame: Baseline and 30 days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07907081.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.